DHA Oral Supplementation Modulates Serum Epoxydocosapentaenoic Acid (EDP)‎ Levels in Breast Cancer Patients

Abstract EN

Introduction.

The omega-3 polyunsaturated fatty acids, as docosahexaenoic acid (DHA), are considered mediators regulating the resolution of inflammation during cancer and may be associated with better outcomes.

Epoxydocosapentaenoic acids (EDPs), metabolites of the DHA, are hypothesized to be responsible for some beneficial effects.

In the present study, we aimed to assess the circulating 19,20-EDP levels in breast cancer (BC) patients and in healthy controls before and after DHA oral supplementation and the potential differences in the DHA conversion in 19,20-EDPs between patients with different BC presentations.

Methods.

BC patients and healthy controls were supplemented with DHA (algal oil) for 10 days (2 g/day).

Blood samples were collected at baseline (T0) and after supplementation (T1) to assess EDP (19,20-EDP) serum levels by liquid chromatography spectrometry.

Results.

33 BC patients and 10 controls were studied.

EDP values at T0 were not different between patients and controls.

At T1, we found an increase in 19,20-EDP levels in BC patients (P<0.00001) and in controls (P<0.001), whereas no differences in 19,20-EDPs were present between the two groups; when considering the type of BC presentation, patients with BRCA1/2 mutation showed lower 19,20-EDPs levels with respect to BC patients without the mutation (P=0.03).

According to immunohistochemical subtype, luminal A-like BC patients showed at T1 higher 19,20-EDP levels compared to nonluminal A (P=0.02).

Conclusions.

DHA oral supplementation was associated with increased 19,20-EDP serum levels in BC patients, independent of the type of BC presentation, and in controls.

Patients carrier of BRCA1/2 mutation seem to possess lower ability of DHA epoxidation, whereas luminal A-like BC patients showed higher EDP conversion.

This behavior should be tested in a larger population.